RecruitingPhase 2NCT04935684

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies


Sponsor

University Hospital, Clermont-Ferrand

Enrollment

150 participants

Start Date

Dec 20, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patient aged 18 or over
  • Men and women
  • Patients affiliated with a social-security organization
  • Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)
  • Signed and dated informed consent

Exclusion Criteria8

  • Status of tumor progression at the time of allo-HSCT
  • Inability to understand the protocol (linguistic barrier, cognitive difficulties)
  • Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)
  • Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)
  • Fecal incontinence
  • Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.
  • Pregnant women
  • Patient under guardianship, curatorship or protection of justice

Interventions

DRUGFecal Microbiota Transplantation

Patients randomized in the "FMT group" will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT. The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes.


Locations(20)

Service d'Hématologie Clinique et Thérapie Cellulaire CHU Amiens Picardie - Site Sud

Amiens, France

Service Maladies du sang CHU Angers

Angers, France

Hématologie clinique CHU Besançon

Besançon, France

Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-Ferrand

Clermont-Ferrand, France

Service de thérapie Cellulaire et d'Hématologie Clinique Adulte CHU Estaing - Clermont-Ferrand

Clermont-Ferrand, France

Service hématologie CHU Grenoble

Grenoble, France

Service des Maladies du sang Hôpital HURIEZ, CHRU de Lille

Lille, France

Service de thérapie cellulaire et l'hématologie clinique adulte CHU Limoges

Limoges, France

Service d'Hématologie Centre Hospitalier Lyon Sud

Lyon, France

Service d'Hématologie et de Médecine interne Hôpital Brabois CHRU Nancy

Nancy, France

Service d'Hématologie Clinique CHU Nantes

Nantes, France

Service d'hématologie clinique, département de greffe de moelle CHU Nice

Nice, France

Service d'Hématologie Adultes Hôpital Necker

Paris, France

Service d'Hématologie clinique Hôpital Pitié-Salpêtrière

Paris, France

Service d'hématologie greffe Hôpital St Louis

Paris, France

Hématologie clinique et thérapie cellulaire Hôpital Haut-Lévèque

Pessac, France

Service d'hématologie greffe Hôpital St Louis

Poitiers, France

Département d'hématologie CAC Rouen

Rouen, France

Hématologie clinique Institut de Cancérologie de la Loire

Saint-Etienne, France

IUC T - Oncopôle

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04935684


Related Trials